ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.16
-0.18%
US Tech 100
19,442.40
-0.70%
S&P 500
5,738.17
-0.13%
US Dollar vs CAD
1.35235
0.34%
Bitcoin
65,808.79
0.96%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Ab Science Sa (0Q77)

  7. Ab Science Sa (0Q77) News

0Q77

Ab Science (0Q77)

Ab Science Sa
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0Q77
DateTimeSourceHeadlineSymbolCompany
09/26/20241:28AMUK RegulatoryAB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangementLSE:0Q77Ab Science Sa
09/26/20241:28AMUK RegulatoryAB Science fait aujourd'hui le point sur le programme microtubule AB8939 et en particulier sur la capacité d'AB8939 à générer une réponse sur le réarrangement du gène MECOMLSE:0Q77Ab Science Sa
09/23/202410:51AMUK RegulatoryAB Science fait aujourd'hui le point sur le développement du masitinib dans les formes progressives de la sclérose en plaques suite à la conférence ECTRIMS 2024LSE:0Q77Ab Science Sa
09/23/202410:51AMUK RegulatoryAB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024LSE:0Q77Ab Science Sa
03/13/20246:58AMUK RegulatoryAB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmuneLSE:0Q77Ab Science Sa
03/13/20246:58AMUK RegulatoryAB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseLSE:0Q77Ab Science Sa
03/07/20248:20AMUK RegulatoryAB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science developmentLSE:0Q77Ab Science Sa
03/07/20248:20AMUK RegulatoryAB Science propose un résumé de la conférence virtuelle qui s’est tenue le 4 mars 2024, avec pour objectif de faire le point sur le développement d'AB ScienceLSE:0Q77Ab Science Sa
03/06/20241:21PMUK RegulatoryAB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the CompanyLSE:0Q77Ab Science Sa
03/06/20241:21PMUK RegulatoryAB Science annonce l’initiation de la couverture de son titre par deux sociétés d’analyse financières, DNA Finance d’une part, et par In Extenso Finance d’autre partLSE:0Q77Ab Science Sa
03/01/202411:07AMUK RegulatoryAB Science tiendra une conférence virtuelle le lundi 4 mars 2024, de 18h30 à 19h30LSE:0Q77Ab Science Sa
03/01/202411:07AMUK RegulatoryAB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CETLSE:0Q77Ab Science Sa
02/29/20244:49AMUK RegulatoryAB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CETLSE:0Q77Ab Science Sa
02/29/20244:49AMUK RegulatoryAB Science tiendra une conférence virtuelle le lundi 4 mars 2024, de 18h30 à 19h30LSE:0Q77Ab Science Sa
02/26/202411:32AMUK RegulatoryAB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALSLSE:0Q77Ab Science Sa
02/26/202411:32AMUK RegulatoryAB Science annonce que Santé Canada a émis un Avis de Non-Conformité-Retrait (ANC-R) pour le masitinib dans la SLALSE:0Q77Ab Science Sa
01/26/202411:01AMUK RegulatoryAB Science fait le point sur la demande d’autorisation de mise sur le marché du masitinib dans la sclérose latérale amyotrophique auprès de l’Agence Européenne des MédicamentsLSE:0Q77Ab Science Sa
01/26/202411:01AMUK RegulatoryAB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines AgencyLSE:0Q77Ab Science Sa
 Showing the most relevant articles for your search:LSE:0Q77

Your Recent History

TG
FTG2
First Trust Us Ipo Index...
BIT
UI143P
Unicredit
COIN
CCTGBP
USOTC
ICHBF
Industrias Ch Sa de Cv Ich (CE)
EU
BPCIS
BPCE SFH BPCESFH3.070%SE...
BOV
GUAR3M
GUARARAPES ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved